Literature DB >> 32270478

Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.

Andreas Schlicker1, Architha Ellappalayam2, Ines J Beumer2, Mireille H J Snel2, Lorenza Mittempergher2, Begona Diosdado3, Christa Dreezen2, Sun Tian2, Ramon Salazar4, Fotios Loupakis5, Filippo Pietrantonio6,7, Cristina Santos Vivas4, Maria Mercedes Martinez-Villacampa4, Alberto Villanueva8, Xavier Sanjuán9, Marta Schirripa5, Matteo Fassan10, Antonia Martinetti6, Giovanni Fucà6, Sara Lonardi5, Ulrich Keilholz11, Annuska M Glas2, René Bernards2,3, Loredana Vecchione11,12.   

Abstract

To date, no systematic analyses are available assessing concordance of molecular classifications between primary tumors (PT) and matched liver metastases (LM) of metastatic colorectal cancer (mCRC). We investigated concordance between PT and LM for four clinically relevant CRC gene signatures. Twenty-seven fresh and 55 formalin-fixed paraffin-embedded pairs of PT and synchronous LM of untreated mCRC patients were retrospectively collected and classified according to the MSI-like, BRAF-like, TGFB activated-like and the Consensus Molecular Subtypes (CMS) classification. We investigated classification concordance between PT and LM and association of TGFBa-like and CMS classification with overall survival. Fifty-one successfully profiled matched pairs were used for analyses. PT and matched LM were highly concordant in terms of BRAF-like and MSI-like signatures, (90.2% and 98% concordance, respectively). In contrast, 40% to 70% of PT that were classified as mesenchymal-like, based on the CMS and the TGFBa-like signature, respectively, lost this phenotype in their matched LM (60.8% and 76.5% concordance, respectively). This molecular switch was independent of the microenvironment composition. In addition, the significant change in subtypes was observed also by using methods developed to detect cancer cell-intrinsic subtypes. More importantly, the molecular switch did not influence the survival. PT classified as mesenchymal had worse survival as compared to nonmesenchymal PT (CMS4 vs CMS2, hazard ratio [HR] = 5.2, 95% CI = 1.5-18.5, P = .0048; TGFBa-like vs TGFBi-like, HR = 2.5, 95% CI = 1.1-5.6, P = .028). The same was not true for LM. Our study highlights that the origin of the tissue may have major consequences for precision medicine in mCRC.
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Entities:  

Keywords:  colorectal cancer molecular classification; gene expression profile of primary and synchronous liver metastasis; molecular concordance between primary and liver metastasis

Mesh:

Substances:

Year:  2020        PMID: 32270478     DOI: 10.1002/ijc.33003

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging.

Authors:  Esther Strating; Emma Wassenaar; Mathijs Verhagen; Paulien Rauwerdink; Susanne van Schelven; Ignace de Hingh; Inne Borel Rinkes; Djamila Boerma; Arjen Witkamp; Miangela Lacle; Riccardo Fodde; Richard Volckmann; Jan Koster; Kris Stedingk; Frederik Giesel; Remmert de Roos; Alex Poot; Guus Bol; Marnix Lam; Sjoerd Elias; Onno Kranenburg
Journal:  Br J Cancer       Date:  2022-03-16       Impact factor: 9.075

2.  Comparative Analysis of Patient-Matched PDOs Revealed a Reduction in OLFM4-Associated Clusters in Metastatic Lesions in Colorectal Cancer.

Authors:  Takuya Okamoto; David duVerle; Katsuyuki Yaginuma; Yasuko Natsume; Hitomi Yamanaka; Daisuke Kusama; Mayuko Fukuda; Mayuko Yamamoto; Fanny Perraudeau; Upasna Srivastava; Yukie Kashima; Ayako Suzuki; Yuuta Kuze; Yu Takahashi; Masashi Ueno; Yoshiharu Sakai; Tetsuo Noda; Koji Tsuda; Yutaka Suzuki; Satoshi Nagayama; Ryoji Yao
Journal:  Stem Cell Reports       Date:  2021-03-11       Impact factor: 7.765

3.  Spatial Immunology in Liver Metastases from Colorectal Carcinoma according to the Histologic Growth Pattern.

Authors:  Gemma Garcia-Vicién; Artur Mezheyeuski; Patrick Micke; Núria Ruiz; José Carlos Ruffinelli; Kristel Mils; María Bañuls; Natàlia Molina; Ferran Losa; Laura Lladó; David G Molleví
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

4.  Clinical and molecular assessment of an onco-immune signature with prognostic significance in patients with colorectal cancer.

Authors:  Pankaj Ahluwalia; Ashis K Mondal; Meenakshi Ahluwalia; Nikhil S Sahajpal; Kimya Jones; Yasmeen Jilani; Gagandeep K Gahlay; Amanda Barrett; Vamsi Kota; Amyn M Rojiani; Ravindra Kolhe
Journal:  Cancer Med       Date:  2022-02-09       Impact factor: 4.452

5.  Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study.

Authors:  Niek A Peters; Alexander Constantinides; Inge Ubink; Joyce van Kuik; Haiko J Bloemendal; Joyce M van Dodewaard; Menno A Brink; Thijs P Schwartz; Martijn P J K Lolkema; Miangela M Lacle; Leon M Moons; Joost Geesing; Wilhelmina M U van Grevenstein; Jeanine M L Roodhart; Miriam Koopman; Sjoerd G Elias; Inne H M Borel Rinkes; Onno Kranenburg
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

6.  Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer.

Authors:  Peter W Eide; Seyed H Moosavi; Ina A Eilertsen; Tuva H Brunsell; Jonas Langerud; Kaja C G Berg; Bård I Røsok; Bjørn A Bjørnbeth; Arild Nesbakken; Ragnhild A Lothe; Anita Sveen
Journal:  NPJ Genom Med       Date:  2021-07-14       Impact factor: 8.617

7.  Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Sanne Ten Hoorn; Tim R de Back; Dirkje W Sommeijer; Louis Vermeulen
Journal:  J Natl Cancer Inst       Date:  2022-04-11       Impact factor: 13.506

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.